Latest Insider Transactions at Phoenix Biotech Acquisition Corp. (PBAXU)
This section provides a real-time view of insider transactions for Phoenix Biotech Acquisition Corp. (PBAXU). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PHOENIX BIOTECH ACQUISITION CORP. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PHOENIX BIOTECH ACQUISITION CORP.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
2,998,908
-18.74%
|
$0
$0.06 P/Share
|
|
Dec 12
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
1,614,541
-9.16%
|
$0
$0.07 P/Share
|
|
Dec 11
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
1,343,801
-7.09%
|
$0
$0.08 P/Share
|
|
Dec 10
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
1,570,947
-7.65%
|
$0
$0.09 P/Share
|
|
Dec 09
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
850,543
-3.98%
|
$0
$0.11 P/Share
|
|
Dec 06
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
1,236,874
-5.47%
|
$0
$0.12 P/Share
|
|
Oct 10
2024
|
Yk Bioventures Opportunities Gp I, LLC |
SELL
Open market or private sale
|
Indirect |
3,250,000
-12.56%
|
$0
$0.1 P/Share
|
|
Sep 25
2024
|
Stuart M Sloan > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
532,486
-2.47%
|
$0
$0.1 P/Share
|
|
Sep 25
2024
|
Brian G Atwood Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
19,358,578
+49.68%
|
-
|
|
Sep 25
2024
|
Christopher B Ehrlich Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,312,983
+47.84%
|
-
|
|
Sep 25
2024
|
Kathleen Laporte Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
965,997
+50.0%
|
-
|
|
Feb 14
2024
|
Daniel E. Geffken Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
10,002
+50.0%
|
-
|
|
Feb 14
2024
|
Barbara Kosacz Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Caroline M Loewy Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Brian G Atwood Director |
BUY
Other acquisition or disposition
|
Indirect |
248,735
+43.67%
|
-
|
|
Feb 14
2024
|
Brian G Atwood Director |
BUY
Other acquisition or disposition
|
Direct |
125,000
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Chairman and CEO |
BUY
Other acquisition or disposition
|
Indirect |
3,600
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Chairman and CEO |
BUY
Other acquisition or disposition
|
Direct |
478,825
+50.0%
|
-
|
|
Feb 14
2024
|
Christopher B Ehrlich Chairman and CEO |
SELL
Other acquisition or disposition
|
Indirect |
5,296,246
-50.95%
|
-
|
|
Feb 14
2024
|
Kathleen Laporte Director |
BUY
Other acquisition or disposition
|
Direct |
5,828
+50.0%
|
-
|
|
Feb 14
2024
|
Phoenix Biotech Sponsor, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
5,296,246
-50.95%
|
-
|
|
Feb 14
2024
|
Douglas Fisher President |
BUY
Other acquisition or disposition
|
Direct |
43,300
+50.0%
|
-
|
|
Oct 08
2021
|
Douglas Fisher President |
BUY
Other acquisition or disposition
|
Indirect |
10,000
+50.0%
|
-
|
|
Oct 08
2021
|
Christopher B Ehrlich Chairman and CEO |
BUY
Other acquisition or disposition
|
Indirect |
36,733
+4.99%
|
$367,330
$10.0 P/Share
|
|
Oct 08
2021
|
Phoenix Biotech Sponsor, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
36,733
+4.99%
|
$367,330
$10.0 P/Share
|